Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072308 | 0.89 | ATM (0.36) | ALDH1A1USP2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10072092 | 0.88 | KDR (0.39) | — | |
| SCHEMBL10072356 | 0.84 | ROCK2 (0.38) | ALDH1A1ULK1 | |
| SCHEMBL10044786 | 0.83 | ROCK2 (0.38) | ALDH1A1NPC1 | |
| SCHEMBL10072159 | 0.82 | JAK3 (0.40) | ALDH1A1 | |
| SCHEMBL10044759 | 0.82 | FGFR3 (0.39) | ADORA3ALDH1A1HTRA1ULK1 | |
| SCHEMBL10044653 | 0.81 | JAK3 (0.40) | NPC1 | |
| SCHEMBL10044760 | 0.80 | CLK4 (0.41) | CLK4ALDH1A1USP2CYP1A2CYP3A4 | |
| SCHEMBL10072307 | 0.80 | ROCK2 (0.41) | MEN1KMT2ANPC1 | |
| SCHEMBL13305844 | 0.80 | CLK4 (0.48) | CLK4ALDH1A1USP2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | CLK4 1038/4885CLK1 728/4885ADORA3 4573/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | CLK4 1038/4885CLK1 728/4885ADORA3 4573/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | CLK4 1038/4885CLK1 728/4885ADORA3 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.